Celularity Inc. - Class A Common Stock (CELU)

Company presents results from in vivo studies of PT-CD16VS, a genetically modified allogeneic cell therapy derived from human placental circulating T (P-T) cells, in combination with various monoclonal antibodies

Event Will Be Hosted On-site and Aired Virtually Highlighting Research, Clinical and Commercial Progress

Expects the First Quarter of 2024 will be the 4th consecutive quarter of both sequential and quarter-on-quarter net sales growth

Celularity Inc. (Nasdaq: CELU) (“Celularity”), a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, and CH Trading Group LLC (“CH Trading Group”), an international import, export and trading company, today announced that they have entered into an exclusive distribution agreement with the Tamer Group (“Tamer”). The Tamer Group, a leading Middle East healthcare distribution company, will be the exclusive distributor for Celularity’s branded regenerative biomaterial products in Saudi Arabia.

Celularity Inc. (Nasdaq: CELU) (“Celularity”), a U.S.-based biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, and CH Trading Group LLC (“CH Trading Group”), an international import, export and trading company, today announced that they have entered into an exclusive territory distribution agreement. CH Trading Group will act as the exclusive territories distributor of Celularity’s previously announced Halal-Certified products within more than 100 countries. The Product Distribution Agreement for Celularity’s Halal-Certified products provides for a five-year minimum aggregate purchase commitment of US $225 million dollars.

New York, New York, United States - 12-20-2022 (PR Distribution™) -

Celularity Inc. (Nasdaq: CELU) (“Celularity” or “the “Company”), a clinical-stage biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, today announced that it received Halal Certification of its business models, commercial stage biomaterial products, and clinical and investigational stage cellular therapeutic programs, indicating that they have undergone rigorous assessment to determine that they are permissible or acceptable in accordance with Islamic law or Sharia. The certificates were issued under the authority of Circle H International, Inc. (“Circle H”) and offer the Company the ability to serve Islamic markets globally. This announcement supports Celularity’s global expansion strategy, which will ultimately include a presence in the Middle East North Africa (MENA) region and a priority focus on Saudi Arabia.

Celularity, Inc. (Nasdaq: CELU) (“Celularity” or “the Company”), a clinical-stage biotechnology company developing placental-derived allogenic cell therapies and biomaterial products, shared today that Chairperson, Founder and Chief Executive Officer Robert J. Hariri, M.D., Ph.D. addressed the Future Investment Initiative 6th Edition in Riyadh conference sponsored by the Future Investment Initiative (FII) at the plenary session: The Science and Technology for Extending Healthy Human Lifespan.

Palm Beach, FL –August 13, 2021 – FinancialNewsMedia.com News Commentary – The normal aging process is characterized by a progression of physiologic events that occur throughout the life cycle. Changes associated with aging occur throughout the body and are most prominent in the later years. Changes in the musculoskeletal system begin to occur after the third decade and continue into the eighth and ninth decades. The frailty syndrome can be described as a culmination of the effects of these changes on the human body. An article in Today’s Geriatric Medicine says that, although it lacks a standardized clinical definition, older adults’ frailty warrants special considerations in terms of treatment and nutritional needs.  “As normal aging progresses, the musculoskeletal system shows declines in several different areas. The term “sarcopenia” describes the biochemical changes that occur within the muscle fibers as they relate to declining muscle mass and muscle function. Visible atrophy of muscle fibers results in decreased strength. These changes result from fat deposition replacing lean muscle mass, a process that begins after the third decade of life and can result in up to a 40% decrease in muscle mass by the eighth decade of life. Marked losses in muscle strength and decreased endurance become more prominent over time and correlate with an increased risk of falls.”  Active Companies in the markets today include Longeveron Inc. (NASDAQ: LGVN), Celularity Inc. (NASDAQ: CELU), CohBar, Inc. (NASDAQ: CWBR), Geron Corporation (NASDAQ: GERN), Athersys, Inc. (NASDAQ: ATHX).